Neuroone Medical Technologies vs InspireMD
Neuroone Medical Technologies reported revenue of $9 million in fiscal 2025, about the same as InspireMD's $9 million in fiscal 2025. Neuroone Medical Technologies' revenue grew 163.5% in its latest year, and InspireMD's grew 28.1%. Neuroone Medical Technologies had an operating margin of -46.5%, against -552.6% at InspireMD. Free cash flow was −$3 million at Neuroone Medical Technologies and −$37 million at InspireMD. Their fiscal years end in different months (September 30 and December 31), so the periods don't line up exactly.
Side by side
| Neuroone Medical Technologies | InspireMD | |
|---|---|---|
| Latest fiscal year | FY2025, Sep 30, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $9M | $9M |
| Revenue growth | 163.5% | 28.1% |
| Revenue growth a year, last 5 years | — | 29.2% |
| Gross margin | 56.5% | 29.5% |
| Operating margin | −46.5% | −552.6% |
| Net margin | −39.6% | −543.3% |
| Free cash flow | −$3M | −$37M |
| Free cash flow margin | −32.1% | −409.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 50.0% | 53.4% |
| Last close | $0.67 | $0.62 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $736,999, sold $54,879 | bought $420,805, sold $126,869 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Neuroone Medical TechnologiesInspireMD
Operating margin
Percent of revenue
Neuroone Medical TechnologiesInspireMD
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Neuroone Medical TechnologiesInspireMD
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Neuroone Medical Technologies and InspireMD pages.